Transforming Treatment Paradigms

Pioneering ApoL1 Targeted Therapies

At Annate Bitherapeutics, we’re pioneering a new class of ApoL1-based therapeutics designed to tackle some of the hardest-to-treat cancers. By harnessing ApoL1’s unique biology, we’re creating precision therapies that act through a completely new mechanism—offering the potential for safer, more effective treatment options.

Our lead programs target multiple myeloma and pancreatic cancer, two diseases that remain among the most challenging in oncology. Backed by strong science and a clear clinical path, Annate is building a pipeline that redefines how cancer can be treated. We’re driven by a simple goal: to turn breakthrough biology into transformative medicines for patients who need them most.

Current Projects

Program
Research
Lead Optimization
IND Enabling
Clinical
Partners

ANN-01M

Multiple Myeloma View details →

Research
100%
Lead Optimization
20%
IND Enabling
0%
Clinical
0%
uga
gra

ANN-01P

Mesothelin-expressing cancers (focus: PDAC) View details →

Research
80%
Lead Optimization
0%
IND Enabling
0%
Clinical
0%
uga
emory
ctsa
  • Last updated October 5th, 2025